Prognostic significance of the CA 125 initial half-life measured during first-line chemotherapy in 62 patients with epithelial ovarian cancer stage III or IV;Valuer pronostique de la demi-vie initiale du CA 125 mesuree au cours de la chimiotherapie d'induction chez 62 patientes porteuses de tumeur epitheliale ovarienne stade III ou IV

Bulletin du Cancer

Volumn 83, Issue 8, 1996, Pages 654-663

  Riedinger, J M ^a   Barillot, I ^a   Coudert, B ^a   Fargeot, P ^a   Berriolo Riedinger, A ^a   Guerrin, J ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

CA 125; first line chemotherapy; half life; ovarian cancer; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROGNOSIS; BLOOD; CANCER STAGING; CARCINOMA; COMPARATIVE STUDY; HALF LIFE TIME; IMMUNOLOGY; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; REGRESSION ANALYSIS; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; HALF-LIFE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0029763367     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Alvarez RD, To A, Boots LR et al. CA 125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol 1987;26:284-9
2. Bast RC, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7
3. Berek JS, Knapp RC, Malkasian GD et al. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986;67:685-9
4. Bordes M, Riedinger JM, Roignot P, Dusserre P. CA 125, CA 19-9 et ACE dans le diagnostic et le suivi des tumeurs ovariennes primitives épithéliales : intérêt et limites.Cancer Commun 1988;2:367-80
5. Buller RE, Berman ML, Bloss JD, Manetta A, Di Saia PJ. CA 125 regression: a model for epithelial ovarian cancer response. Am J Obstet Gynecol 1991;165:360-7
6. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984;50:765-9
7. Cruickshank DJ, Paul J, Lewis CR, Mc Allister EJ, Kaye SB. An independent evaluation of the potential clinical usefulness of proposed CA 125 indices previously shown to be of prognostic significance in epithelial ovarian cancer. Br J Cancer 1992;65:587-600
8. Fisken J, Leonard RCF, Stewart M et al. The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.. Br J Cancer 1993;68:140-5
9. Goel R, Nelson J, Kirmani S, McVey L, Kim S, Howel SB. Prognostic value of CA 125 half-life in ovarian cancer patients. Proc Am Soc Clin Oncol 1990;9:166
10. Hand R, Fremgen A, Chmiel JS et al. Staging procedures, clinical management, and survival outcome for ovarian carcinoma. J Am Med Assoc 1993;269:1119-22
11. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, Fryatt IJ, Mc Cready VR. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynecol 1989;96:1395-9
12. Högberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian cancer. Ada Obstet Gynecol Scand 1990;69:423-9
13. Hunter VJ, Daly L, Helms M et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990;163:1164-7
14. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 1987;69:223-7
15. Niloff JM, Bast RC, Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985; 151:981-6
16. Redman CWE, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley DM. Early serum CA 125 response and out-come in epithelial ovarian cancer. Eur J Cancer 1990;26:593-6
17. Riedinger JM, Barillot I, Lizard-Nacol S et al.Epithelial ovarian carcinoma: prognostic value of serum CA 125 doubling time prior to clinically evident relapse (résumé). Eur J Nucl Med 1994;21:730
18. Rosman M, Hayden CL, Thiel RP et al. Prognostic indicators for poor risk epithelial ovarian carcinoma Cancer 1994;74:1323-8
19. Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshave KD. Use of CA 125 to predict survival of pathients with ovarian carcinoma. J Clin Oncol 1989;7:1667-71
20. Talbot RW, Jacobsen DJ, Nagorney, Malkasian GD, Ritts RE. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 1989;168:407-12
21. Van der Burg MEL, Lammes FB, Van Putten WLJ, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncology 1988;30:307-12
22. Van der Zee AGJ, Duk JM, Aalders JG, Boontje AH, Ten Hoor KA, De Bruijn HWA. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynecol 1990;97:934-8
23. Willemse PHB, Aalders JG, de Bruyn HWA, Mulder NH, Sleijfer DTh, de Vries EGE. CA 125 in ovarian cancer: relation between half-life, doubling time and survival. Eur J Cancer 1991;27:993-5
24. Yedema CA, Kenemans P, Thomas CM et al. CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 1993;29A:966-71
25. Yedema CA, Kenemans P, Voorhorst F et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993;67:1361-7